

## Antileukinate

<b>Cat. No.:</b>	HY-125567
<b>CAS No.:</b>	138559-60-1
<b>Molecular Formula:</b>	C <sub>45</sub> H <sub>66</sub> N <sub>18</sub> O <sub>7</sub> S
<b>Molecular Weight:</b>	1003.19
<b>Sequence Shortening:</b>	Ac-RRWWCR-NH <sub>2</sub>
<b>Target:</b>	CXCR
<b>Pathway:</b>	GPCR/G Protein; Immunology/Inflammation
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury <sup>[1][2][3]</sup> .
<b>In Vitro</b>	Antileukinate inhibits the binding of human eotaxin to human eosinophils with an IC <sub>50</sub> of 8.2 μM <sup>[2]</sup> . Antileukinate (10-100 μM; 2 hours) significantly suppresses eosinophil chemotaxis to human eotaxin <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Antileukinate (52.63 mg/kg; s.c.) protects mice against acute pancreatitis and associated lung injury <sup>[1]</sup> . Antileukinate (5mg/kg; s.c.) inhibits the interaction between murine eotaxin and murine eosinophil <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>Animal Model:</b>	Swiss mice (20-25g) <sup>[1]</sup>
<b>Dosage:</b>	52.63 mg/kg
<b>Administration:</b>	Subcutaneous injection
<b>Result:</b>	Reduced pancreatic edema induced by Caerulein (50 μg/kg).

### REFERENCES

- [1]. Madhav Bhatia, et al. Treatment with antileukinate, a CXCR2 chemokine receptor antagonist, protects mice against acute pancreatitis and associated lung injury. Regul Pept. 2007 Jan 10;138(1):40-8.
- [2]. Yuji Fukuno, et al. Chemokine receptor inhibitor, Antileukinate, suppressed ovalbumin-induced eosinophilic inflammation in the airway. Cytokine. 2003 Jun 7;22(5):116-25.
- [3]. S Hayashi, et al. Antileukinate, a hexapeptide inhibitor of CXC-chemokine receptor, suppresses bleomycin-induced acute lung injury in mice. Lung. 2002;180(6):339-48.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA